Clinical Trial Update: Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

View source ↗

Summary

Clinical trial update comparing idarubicin to daunorubicin in acute myeloid leukemia reports higher induction remission rates and better response quality with i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Daunorubicin (daunorubicin)
• Idarubicin (idarubicin)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Myeloid Leukemia | Status: UNKNOWN